Molecular mechanisms underlying the impact of GLP-1RAs on cancer risk The regulation of cancer risk by GLP-1RAs involves several biological mechanisms, primarily encompassing metabolic regulation, direct anti-tumor effects, immune modulation, and epigenetic alterations
So, how might it help you with hypothyroidism weight gain problems
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
The SURPASS-CVOT trial showed cardiovascular benefit compared to another active GLP-1 treatment , suggesting direct pharmacological effects beyond what weight reduction alone would produce
Future readouts will shed light on retatrutides body composition preservation compared to existing therapies
